Merck KGaA Overcomes Ukraine Disruption To Keep MS Frontrunner On Track

FDA Has Approved Trial Adaptations

 
• By Andrew McConaghie
  
Merck KGaA Darmstadt
Evobrutinib is one of two Phase III assets which Merck KGaA believes can achieve $1bn plus annual revenues • Source: Shutterstock
Scrip Podcast

Have you checked out Scrip podcast?

New episodes every Thursday.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip